Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT05043688Phase 3Active, not recruiting
- Start
- Sep 2021
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC). Started Sep 2021; status: active, not recruiting.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05043688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043688.